Investment Summary

Ampersand Capital Partners Invests In AnaBios

On January 7, 2022, growth capital firm Ampersand Capital Partners invested in life science company AnaBios

Investment Highlights
  • This is Ampersand Capital Partners’ 32nd transaction in the Life Science sector.
  • This is Ampersand Capital Partners’ 58th transaction in the United States.
  • This is Ampersand Capital Partners’ 10th transaction in California.

Investment Summary
Date 2022-01-07
Target AnaBios
Sector Life Science
Investor(s) Ampersand Capital Partners
Deal Type Growth Capital

Target

AnaBios

San Diego, California, United States
AnaBios is a preclinical contract research organization (CRO) that focuses on translational research with unique capabilities to measure drug activity directly in human tissue. AnaBios is based in San Diego, California.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 3.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 66 of 84
Sector (Life Science) 32 of 43
Type (Growth Capital) 19 of 24
State (California) 10 of 12
Country (United States) 58 of 69
Year (2022) 1 of 11
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-18 Resolian

Malvern, Pennsylvania, United States

Resolian is a contract research organization (CRO) that specializes in advanced bioanalytical research services for both small and large molecule drugs, as well as drug metabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs. Resolian was founded in 2008 and is headquartered in Malvern, Pennsylvania.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-01-10 Nexelis

Laval, Quebec, Canada

Nexelis is an immunology-centric CRO specialized in preclinical models and clinical assay development in single and multiplex formats and sample analysis for low-, mid- and large-scale clinical testing. the company's team of scientists and technology platforms have been instrumental in the development, qualification, and validation of assays supporting FDA filings of over 100 new molecular entities, including blockbuster biologics such as vaccines and complex large molecules.

Sell -
Mergr

Product

Company

Legal